Comprehensive Eye Cancer Website Meets Needs of Both Patients and Physicians

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 9
Volume 9
Issue 9

NEW YORK-Visitors to the Eye Cancer Network (ECN) website (www.eyecancer.com) can access a wealth of information on ocular cancers, including an extensive collection of clinical photographs (see images). The site is well designed, leading visitors logically and quickly to specific information and related links. For example, a visitor seeking information on retinal tumors easily finds the topic in the Eye Conditions index, where it is subdivided into retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, and von Hippel angioma.

NEW YORK—Visitors to the Eye Cancer Network (ECN) website (www.eyecancer.com) can access a wealth of information on ocular cancers, including an extensive collection of clinical photographs (see images). The site is well designed, leading visitors logically and quickly to specific information and related links. For example, a visitor seeking information on retinal tumors easily finds the topic in the Eye Conditions index, where it is subdivided into retinoblastoma, retinal pigment epithelial tumors, retinal pigment epithelial hypertrophy, and von Hippel angioma.

Webmaster Paul T. Finger, MD, is director of The New York Eye Cancer Center, which he established; director of the Ocular Tumor Service, The New York Eye and Ear Infirmary; and associate professor of ophthalmology, New York University School of Medicine. He is also principal investigator for the Collaborative Ocular Melanoma Study, sponsored by the National Institutes of Health and National Eye Institute.

The EyeCancer Network site is designed to meet the needs of both patients and physicians. Patients can seek out information on the eye and eye conditions written for the layperson, visit a frequently asked questions section, or search for a physician in the physician finder. But they also have access to the site’s wide array of clinical information, including sections on innovative treatments, NCI-funded studies, and ophthalmology meetings.

Of special interest is ECN Interactive, a bulletin board where patients can share their personal experiences in the “Heart 2 Heart” section, while physicians can discuss their clinical experiences in the “Eye 2 Eye” discussion forum.

Dr. Finger has also started the Online Journal of Ophthalmic Oncology (OJO), available on the ECN website. The journal will publish original laboratory and clinical investigations related to ophthalmic oncology. All manuscripts will be reviewed by a minimum of two specialists in ophthalmic oncology and/or related specialties, and accepted articles will be accessible to readers worldwide for a minimum of 1 year.

The Eye Care Foundation, established by Dr. Finger, is also featured on the website. The mission of this nonprofit organization is to provide up-to-date treatment information to patients and physicians, establish family and patient support programs, empower patients to find the resources they need, fund and direct research to find cures for eye diseases, and coordinate national and international prospective, randomized clinical trials to evaluate new methods of diagnosis and treatment.

Recent Videos
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Related Content